Most-used outcome measurements in clinical trials from 2018 to 2019 for plaque psoriasis

被引：0
|
作者：
Kamrani, Payvand [1 ]
Bashyam, Arjun [2 ]
Feldman, Steven [2 ]
机构：
[1] Wake Forest Sch Med, Dept Dermatol, Winston Salem, NC 27101 USA
[2] Wake Forest Sch Med, Winston Salem, NC 27101 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
17638
引用
收藏
页码：AB196 / AB196
页数：1
相关论文
共 50 条
  • [1] An overview of the most commonly used venous quality of life and clinical outcome measurements
    Catarinella, Fabio S.
    Nieman, Fred H. M.
    Wittens, Cees H. A.
    [J]. JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2015, 3 (03) : 333 - 340
  • [2] Regarding "An overview of the most commonly used venous quality of life and clinical outcome measurements"
    Lattimer, Christopher R.
    Kalodiki, Evi
    Geroulakos, George
    [J]. JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2015, 3 (04) : 465 - 465
  • [3] Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
    Reich, Kristian
    Thaci, Diamant
    Stingl, Georg
    Andersen, Jens Strodl
    Hiort, Line Conradsen
    Lexner, Michala Oron
    Winkler, David
    Paul, Carle
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [4] Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
    Romiti, R.
    Valenzuela, F.
    Chouela, E. N.
    Xu, W.
    Pangallo, B.
    Moriarty, S. R.
    Gurbuz, S.
    Riedl, E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (01) : 202 - 203
  • [5] Current Psoriasis Efficacy Outcome Measures in Clinical Trials
    Wechter T.
    Heath M.
    Aung-Din D.
    Sahni D.
    Cline A.
    Feldman S.R.
    [J]. Current Dermatology Reports, 2018, 7 (4) : 261 - 268
  • [6] Regarding "An overview of the most commonly used venous quality of life and clinical outcome measurements" Reply
    Catarinella, Fabio S.
    Nieman, Fred H. M.
    Wittens, Cees H. A.
    [J]. JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2015, 3 (04) : 466 - 466
  • [7] INCIDENCE OF INFECTIONS IN CLINICAL TRIALS OF TILDRAKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS
    Crowley, Jeffrey
    Leonardi, Craig
    Sturgill-Koszycki, Sheila
    Menter, Alan
    Mendelsohn, Alan
    Li, Qing
    Cichanowitz, Nicole
    La Rosa, Carmen
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 28 - 28
  • [8] Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials
    Gottlieb, A. B.
    Thaci, D.
    Leonardi, C.
    Poulin, Y.
    Kavanagh, S.
    Boehnlein, M.
    Reich, K.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 54 - 54
  • [9] INCIDENCE OF INFECTIONS IN CLINICAL TRIALS OF TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
    Crowley, J.
    Leonardi, C.
    Sturgill-Koszycki, S.
    Menter, A.
    Mendelsohn, A. M.
    Li, Q.
    Cichanowitz, N.
    La Rosa, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1020 - 1021
  • [10] A review of malignancies observed during efalizumab (Raptiva®) clinical trials for plaque psoriasis
    Leonardi, Craig L.
    Toth, Darryl
    Cather, Jennifer C.
    Langley, Richard G. B.
    Werther, Winifred
    Compton, Peter
    Kwon, Paul
    Wetherill, Graham
    Curtin, Francois
    Menter, Alan
    [J]. DERMATOLOGY, 2006, 213 (03) : 204 - 214
12345